60 Degrees Pharmaceuticals, Inc. Files Updated Legal Opinion for ATM Equity Offering

Key Points:

• On March 13, 2026, 60 Degrees Pharmaceuticals, Inc. (“the Company”) filed a Current Report on Form 8-K announcing the submission of an updated legal opinion regarding its “at-the-market” (ATM) equity offering program.
• The updated legal opinion, issued by Sichenzia Ross Ference Carmel LLP, pertains to the validity of shares issued and sold under the ATM Program, which is conducted pursuant to a Sales Agreement with HC Wainwright & Co., LLC, dated September 5, 2025.
• The legal opinion confirms that the shares issued under the ATM Program are validly issued, fully paid, and non-assessable.
• The ATM Program allows 60 Degrees Pharmaceuticals, Inc. to offer and sell up to \$565,000 of common stock, par value \$0.0001 per share, through its agent HC Wainwright & Co., LLC.
• The filing includes key exhibits: the legal opinion (Exhibit 5.1) and the consent of counsel (Exhibit 23.1), as well as the Inline XBRL cover page data (Exhibit 104).
• The updated legal opinion does not alter the terms of the ATM Program but provides legal assurance regarding the shares’ validity and compliance with applicable law.
• 60 Degrees Pharmaceuticals, Inc. is an emerging growth company, and the filing notifies investors that the company has not elected to use the extended transition period for complying with new or revised financial accounting standards.
• The common stock (trading symbol: SXTP) and warrants (trading symbol: SXTPW) are listed on Nasdaq Stock Market LLC.
• The report was signed by Geoffrey Dow, Chief Executive Officer and President.

Details Investors Should Know:

• Price Sensitivity: While the filing of a legal opinion itself is procedural, it is critical for investors to note that this updated opinion reinforces the legality and validity of shares issued under the ATM Program. This is important for investor confidence and could affect perceptions about the company’s compliance and risk profile.
• ATM Program Capacity: The ATM Program provides the company flexibility to raise up to \$565,000 in capital via common stock sales. Any sales executed under the program could increase the float and potentially affect share prices, especially if large volumes are sold.
• Confirming Share Validity: The legal opinion means investors can be assured that any shares purchased under the ATM Program are fully authorized and compliant with Delaware and federal law.
• Emerging Growth Company Status: The company discloses its status as an emerging growth company, which may allow it to take advantage of certain reduced reporting requirements and exemptions. However, it has not opted out of using the extended transition period for accounting standards, meaning it will adopt new standards as they become effective.
• No Changes to ATM Terms: The filing explicitly states the updated legal opinion does not change the terms of the ATM equity offering.

Potential Share Price Impact:

• As the ATM Program enables ongoing sales of common stock, investors should monitor the company’s announcements regarding actual sales volumes, as these could dilute existing holdings and impact market prices.
• The confirmation of share validity and legal compliance may positively affect investor confidence, but the actual impact on share price depends on the company’s future use of the ATM facility and market conditions.
• No material events or changes to the ATM Program terms were reported, so the immediate price impact may be limited unless the company announces significant sales or other developments.

Other Information:

• The company’s shares and warrants are registered and actively traded on Nasdaq.
• No written communications, soliciting materials, or pre-commencement tender offers were checked as being applicable in this filing.
• The legal opinion restricts its use to this specific filing and ATM program, and does not cover other purposes or future changes.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The information is based on public filings made by 60 Degrees Pharmaceuticals, Inc. Investors should conduct their own due diligence and consult a financial advisor before making investment decisions. Past filings and legal opinions do not guarantee future results or compliance. The company’s use of the ATM Program may impact share prices depending on the volume and timing of sales.

View 60 DEGREES PHARMACEUTICALS, INC. Historical chart here